The CEDAR Study: A longitudinal study of the clinical effects of conventional DMARDs and biologic DMARDs in Australian rheumatology practice
-
Altmetric Citations
Roberts, L; Tymms, Kathleen; de Jager, Julien; Littlejohn, Geoffrey; Griffiths, Hedley; Nicholls, Dave; BIRD, Paul; Young, J; Hill, Julie; Zochling, Jane
Description
Objectives. To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs (bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival and determine the effect of cDMARDs/bDMARDs on disease activity. Methods. Routinely collected, deidentified clinical data was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs and a recorded...[Show more]
dc.contributor.author | Roberts, L | |
---|---|---|
dc.contributor.author | Tymms, Kathleen | |
dc.contributor.author | de Jager, Julien | |
dc.contributor.author | Littlejohn, Geoffrey | |
dc.contributor.author | Griffiths, Hedley | |
dc.contributor.author | Nicholls, Dave | |
dc.contributor.author | BIRD, Paul | |
dc.contributor.author | Young, J | |
dc.contributor.author | Hill, Julie | |
dc.contributor.author | Zochling, Jane | |
dc.date.accessioned | 2021-09-27T01:01:40Z | |
dc.date.available | 2021-09-27T01:01:40Z | |
dc.identifier.issn | 1687-9260 | |
dc.identifier.uri | http://hdl.handle.net/1885/248742 | |
dc.description.abstract | Objectives. To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs (bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival and determine the effect of cDMARDs/bDMARDs on disease activity. Methods. Routinely collected, deidentified clinical data was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs and a recorded subsequent visit, were included. A linear mixed model was used to determine the change over time and the percentage reduction in disease activity was summarized. Results. 12,526 RA patients were included: 72% females, mean age 62 years. cDMARDs and bDMARDs were used in 92% and 30% of patients, respectively. The most commonly prescribed cDMARD was methotrexate (76% patients); median time to stopping treatment was 337 months [95% CI: 279–ND]. Etanercept was the most commonly prescribed bDMARD (12% patients); median time to stopping treatment was 79 months [95% CI: 57–93]. Of 5,341 patients with a first change in medication (cDMARD or bDMARD), 87% had therapy escalation and 13% deescalation. Reduction in DAS28-ESR, 6-month post-DMARDs initiation ranged from 3%, adalimumab, to 14%, leflunomide and tocilizumab. Conclusions. In this large Australian cohort of unselected community RA patients, the choices of cDMARDs/bDMARDs are aligned with current international guidelines | |
dc.description.sponsorship | This work was supported by Roche Products Pty Limited (Australia). | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en_AU | |
dc.publisher | Hindawi Publishing Corporation | |
dc.rights | Copyright © 2017 Lynden Roberts et al. | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | International Journal of Rheumatology | |
dc.title | The CEDAR Study: A longitudinal study of the clinical effects of conventional DMARDs and biologic DMARDs in Australian rheumatology practice | |
dc.type | Journal article | |
local.description.notes | Imported from ARIES | |
local.identifier.citationvolume | 2017 | |
dc.date.issued | 2017 | |
local.identifier.absfor | 110322 - Rheumatology and Arthritis | |
local.identifier.ariespublication | a383154xPUB7400 | |
local.publisher.url | https://www.hindawi.com/ | |
local.type.status | Published Version | |
local.contributor.affiliation | Roberts, L, Monash University | |
local.contributor.affiliation | Tymms, Kathleen, College of Health and Medicine, ANU | |
local.contributor.affiliation | de Jager, Julien, Gold Coast Rheumatology | |
local.contributor.affiliation | Littlejohn, Geoffrey, Monash University | |
local.contributor.affiliation | Griffiths, Hedley, Barwon Rheumatology Service | |
local.contributor.affiliation | Nicholls, Dave, Coast Joint Care | |
local.contributor.affiliation | BIRD, Paul, Combined Rheumatology Practice | |
local.contributor.affiliation | Young, J, Roche Products Propriety Limited | |
local.contributor.affiliation | Hill, Julie, McCloud Consulting Group | |
local.contributor.affiliation | Zochling, Jane, The Menzies Institute | |
local.bibliographicCitation.startpage | 1201450 | |
local.bibliographicCitation.lastpage | 1201450 | |
local.identifier.doi | 10.1155/2017/1201450 | |
dc.date.updated | 2020-11-23T11:15:09Z | |
local.identifier.scopusID | 2-s2.0-85021724297 | |
local.identifier.thomsonID | 000401723700001 | |
dcterms.accessRights | Open Access | |
dc.provenance | This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.rights.license | Creative Commons Attribution License | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Roberts_The_CEDAR_Study%3A_A_2017.pdf | 1.53 MB | Adobe PDF |
This item is licensed under a Creative Commons License
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator